Losartan vs Irbesartan

Both losartan and irbesartan effectively lower blood pressure. Irbesartan is generally considered more potent on a milligram basis and provides more consistent 24-hour blood pressure control. At maximum doses, irbesartan 300 mg achieves slightly greater blood pressure reduction than losartan 100 mg in most comparative studies.

For diabetic nephropathy (kidney protection), irbesartan has the stronger evidence base. The IDNT trial demonstrated that irbesartan 300 mg reduced the risk of doubling of serum creatinine by 33% and end-stage renal disease by 23% compared to placebo. The IRMA-2 trial showed irbesartan prevented progression from microalbuminuria to overt nephropathy.

Losartan also has kidney-protective data from the RENAAL trial and uniquely among ARBs has been shown to reduce serum uric acid levels, which may benefit patients with gout or hyperuricemia. Losartan is also FDA-approved for stroke risk reduction in hypertensive patients with left ventricular hypertrophy (LIFE trial).

Both losartan and irbesartan are very well tolerated, with side effect profiles similar to placebo in clinical trials. Common side effects include dizziness, upper respiratory infection, and fatigue.

Both drugs carry the class-wide ARB warnings: they should not be used during pregnancy (can cause fetal harm), can cause hyperkalemia (elevated potassium), and may worsen renal function in patients with bilateral renal artery stenosis.

Losartan has a unique uricosuric effect (increases uric acid excretion), which can be beneficial for patients with gout but may rarely cause uric acid kidney stones in susceptible individuals.

Neither drug has significant CYP450 interactions that would affect most patients, though losartan is partially converted to its active metabolite by CYP2C9.

Both drugs are available as inexpensive generics. Losartan has been generic since 2010 and irbesartan since 2012. A 30-day supply of either typically costs $4-$20.

Losartan is available in combination with hydrochlorothiazide (Hyzaar), and irbesartan is available with hydrochlorothiazide (Avalide), both as generics. Cost differences between the two ARBs are negligible.

Both are taken once daily as oral tablets. Neither requires food for absorption. Irbesartan achieves its full effect with once-daily dosing due to its long duration of action. Some patients on losartan may require twice-daily dosing for full 24-hour blood pressure coverage, though once daily is the standard recommendation.

Losartan is available in 25 mg, 50 mg, and 100 mg tablets. Irbesartan comes in 75 mg, 150 mg, and 300 mg tablets. Both allow straightforward dose titration.

Irbesartan may be preferred when maximal blood pressure control and diabetic nephropathy protection are priorities, given its stronger evidence in the IDNT and IRMA-2 trials and its longer duration of action.

Losartan may be preferred for patients with concomitant gout or hyperuricemia (due to its uricosuric effect), for stroke prevention in patients with left ventricular hypertrophy, or simply due to clinician familiarity as the most commonly prescribed ARB.

Both are excellent, well-tolerated medications. The choice between them is often guided by specific comorbidities and provider preference. Consult your healthcare provider for personalized guidance.